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Background: Serotype M4 group A Streptococcus lack hyaluronic acid (HA) capsule, but are capable of causing human
disease.
Results: Encapsulation was achieved by introducing the hasABC capsule synthesis operon in the absence of HA-degrading
enzyme hyaluronate lyase (HylA).
Conclusion: Capsule expression does not enhance M4 GAS virulence.
Significance:We demonstrate a mutually exclusive interaction between GAS capsule and HylA expression.
A recent analysis of group A Streptococcus (GAS) invasive
infections in Australia has shown a predominance ofM4GAS, a
serotype recently reported to lack the antiphagocytic hyaluronic
acid (HA) capsule. Here, we use molecular genetics and bioin-
formatics techniques to characterize 17 clinical M4 isolates
associated with invasive disease in children during this recent
epidemiology. All M4 isolates lacked HA capsule, and whole
genome sequence analysis of two isolates revealed the complete
absence of the hasABC capsule biosynthesis operon. Con-
versely,M4 isolates possess a functionalHA-degrading hyaluro-
nate lyase (HylA) enzyme that is rendered nonfunctional in
other GAS through a point mutation. Transformation with a
plasmid expressing hasABC restored partial encapsulation in
wild-type (WT) M4 GAS, and full encapsulation in an isogenic
M4 mutant lacking HylA. However, partial encapsulation
reduced binding to human complement regulatory protein
C4BP, did not enhance survival in whole human blood, and did
not increase virulence of WTM4 GAS in a mouse model of sys-
temic infection. Bioinformatics analysis found no hasABC
homologs in closely related species, suggesting that this operon
was a recent acquisition. These data showcase amutually exclu-
sive interaction of HA capsule and active HylA among strains of
this leading human pathogen.
The Gram-positive bacterium Streptococcus pyogenes, com-
monly known as group A Streptococcus (GAS),3 is a human-
specific pathogen ranked among the top 10 etiological agents of
infection-related deaths worldwide (1). Annually, GAS is
responsible for 700 million cases of superficial throat (phar-
yngitis) and skin (impetigo) infections and 650,000 cases of
potentially fatal severe invasive infections (e.g. bacteremia/sep-
sis, necrotizing fasciitis, and streptococcal toxic shock syn-
drome), with an attendant mortality rate of 25% (1). GAS
strains are distinguished serologically on the basis of the immu-
novariable M protein (2), a major surface-anchored virulence
factor that promotes resistance to opsonophagocytosis (3).
Throughout much of the world, M1 is the most frequently iso-
lated serotype fromGAS infections, followed by serotypesM12,
M28, M3, and M4 (4). A key factor in the resurgence of severe
invasive GAS infections over the past 30 years has been the
global dissemination of a hypervirulent clone belonging to the
M1T1 serotype (5).
The surface capsule ofGAS is composed solely of hyaluronan
or hyaluronic acid (HA), a high molecular mass polymer of
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alternating glucuronic acid and N-acetylglucosamine residues.
The GAS capsule is structurally identical to the HA widely dis-
tributed throughout human tissues, allowing GAS to mimic
host structures and thwart detection by the host immune sys-
tem (5). The capsule promotes GAS survival by obstructing
antibody binding to epitopes on the bacterial surface, comple-
ment deposition (6), and opsonophagocytosis (6, 7). Capsular
HA contributes to mouse pharyngeal colonization (8), and
interactswithCD44onhumankeratinocytes to enhance adher-
ence to pharyngeal epithelial cells (9). Nonencapsulated GAS
mutants have significantly reduced survival in human blood
and are less virulent than encapsulated WT strains in mouse
models of invasive GAS infection (10–13), and a nonhuman
primate model of pharyngeal colonization (14).
HA capsule biosynthesis is coordinated by the highly con-
servedhasABC synthase operon (15). ThehasA gene is essential
for HA biosynthesis and encodes for hyaluronate synthase, a
membrane-bound enzyme that forms the linearHApolymer by
the alternate addition of glucuronic acid and 1,3-linked
N-acetylglucosamine residues (16, 17). Capsule expression is
strongly up-regulated upon exposure of GAS to whole human
blood (18), andmucoid or highly encapsulatedGAS isolates are
often associated with pharyngeal persistence, acute rheumatic
fever, and severe invasive human diseases (19). Spontaneously
arising and irreversible mutations in the control of virulence
regulatory system (covRS), a two-component regulator that
coordinates the expression of 10–15% of genes in the GAS
genome (20), have been implicated in the initiation and pro-
gression of GAS invasive disease (5, 21, 22). Mutations in covRS
up-regulate HA capsule biosynthesis and a multitude of viru-
lence factors important for neutrophil resistance (21). Conse-
quently, covRS mutants display enhanced virulence in mouse
models of systemic GAS infection (22). In addition, covRS
mutation abrogates expression of the broad spectrum cysteine
protease streptococcal pyrogenic exotoxin B (SpeB) (21), allow-
ing the accumulation of human plasmin activity on the GAS
surface (23). Plasminogen, a glycoprotein circulating in human
blood, is the inactive form of plasmin, a broad spectrum serine
protease capable of dissolving blood clots and promoting tissue
remodeling (24). Streptokinase is a plasminogen-activating
protein secreted by most GAS isolates that is highly specific for
human plasminogen (25). GAS bind plasmin(ogen) directly
through cell surface receptors, including 1) streptococcal sur-
face enolase (-enolase/SEN) (26); 2) streptococcal surface
dehydrogenase (SDH), also known as glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) and plasmin receptor (27); 3)
plasminogen-bindingM-like protein (28); and 4) plasminogen-
binding M-like protein-related protein (29). Indirect plasmin-
ogen binding may occur through the formation of a streptoki-
nase-plasminogen-fibrinogen (Fg) trimolecular complex that
attaches to Fg or plasminogen receptors on theGAS cell surface
(30). Sequestered plasmin activity on the GAS cell surface
cannot be inhibited by host regulators 2-antiplasmin and
2-macroglobulin (31), allowingGAS to degrade tissue barriers
and spread systemically to normally sterile sites (5, 22, 23).
Although it was long assumed that the HA capsule was an
essential virulence factor of the pathogen, genomic analysis
recently revealed that disease-associatedM4 serotypeGAS lack
the hasABC operon (32), are nonencapsulated, yet neverthe-
less, can replicate in human blood ex vivo (33). During recent
epidemiology of severe invasive GAS infections in Australian
children, M4 GAS surpassed M1 as the serotype most fre-
quently isolated fromnormally sterile sites (34).Here, we utilize
molecular genetics and bioinformatics to investigate the path-
ogenicity of 17 M4 clinical isolates from this emerging epide-
miological trend. Three pulsed-field gel electrophoresis (PFGE)
patterns and 2 multilocus sequence types (MLST) were identi-
fied, withmore than 50%of isolates harboringmutationswithin
covRS, a characteristic of hyperinvasive GAS. All M4 isolates
were nonencapsulated and whole genome sequencing of 2 M4
isolates revealed the complete absence of the hasABC capsule
biosynthesis operon.We identify and functionally demonstrate
a mutually exclusive interaction between GAS HA capsule
expression (most serotypes) and expression of a secreted hy-
aluronate lyase (HylA) (35), which is functional in M4 GAS but
harbors an inactivating mutation in encapsulated strains. The
implications of this dynamic upon GAS invasive disease patho-
genesis and evolution are considered in light of these new
observations.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions—M4 GAS strains
were isolated from children aged 1–14 years hospitalized with
severe invasive infections in Queensland, Australia, between
February 2001 and May 2009 (Table 1) (34). M1T1 GAS strain
5448was isolated fromapatientwith toxic shock syndrome and
necrotizing fasciitis (36). The highly invasive animal passaged
variant, 5448AP, is a hyperencapsulated covSmutant (22). Iso-
genic nonencapsulated mutant 5448hasA was described pre-
viously (37). GAS strain 4063-05 (emm4, T-type 4) was isolated
in 2005 from the blood of a patient in Georgia, USA. GAS was
propagated at 37 °C on Todd-Hewitt agar, or in static liquid
cultures of Todd-Hewitt broth (THB, Hardy Diagnostics).
When necessary, the growthmediumwas supplementedwith 5
g/ml of erythromycin or 2 g/ml of chloramphenicol.
Sequence Typing and PFGE—emm sequence typing was
undertaken using established criteria from the Centers for Dis-
ease Control and Prevention. T-typing was performed essen-
tially as described elsewhere (38). MLST was undertaken using
the primers listed at the Centers for Disease Control and Pre-
vention and the PCR conditions described at the S. pyogenes
MLST database. Genomic DNA digests were compared by
PFGE using the CHEF-DR II System (Bio-Rad) as described
previously (39).
HA Capsule Assays—Capsular HA was extracted according
to the method of Hollands et al. (37). Bacterial cultures were
grown tomid-log phase (A600 0.4) in THB and serially diluted
for colony-forming unit (cfu) enumeration. 5 ml of culture was
centrifuged and resuspended in 500 l of sterile Milli-Q water.
400l of bacterial suspension was added to 1ml of chloroform,
shaken for 5 min in a Mini-BeadBeater-8 (Biospec Products),
and clarified by centrifugation at 13,000 g for 10 min. HA in
the aqueous phase was quantified using the ELISAHATest Kit
(Corgenix), as per the manufacturer’s directions.
Glycan Analysis—HA was purified from the aqueous phase
by DEAE-Sephacel chromatography and analyzed by high-
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performance anion-exchange chromatography with pulsed
amperometric detection (HPAEC-PAD) for monosaccharides
representing HA. Briefly, HA present in the aqueous phase was
loaded on the DEAE column and washed with 5 ml of 50 mM
NaOAc, 150mMNaCl solution (pH 6.0) to remove contaminat-
ing protein. DEAE-bound HA was eluted with 1 ml of 50 mM
NaOAc, 1 M NaCl (pH 6.0) solution. High salt was removed by
desalting the sample over a PD10 cartridge (GE Healthcare).
Finally, the sample was lyophilized and used for monosaccha-
ride analysis. HA was hydrolyzed to monosaccharide constitu-
ents using 2 N trifluoroacetic acid (TFA) at 100 °C for 6 h. TFA
was removed by dry nitrogen flush followed by two times co-
evaporation with 50% isopropyl alcohol to ensure complete
removal of acid. Finally the sample was dissolved in water and
monosaccharide profiling was done on the Dionex ICS-3000
using the CarboPac PA1 column (4  250 mm; Dionex).
NaOH/NaOAcbuffer gradientwas used as eluent and themon-
osaccharides were compared and quantified using known
amounts of authentic standards as external calibrants.
Multiplex PCR Screening—A conserved 561-bp region of
hasA was amplified with primers hasA-F1 (5-aatacaattaattga-
agagtatgtaaatagaga-3) and hasA-R1 (5-attttgttgctttaaataactt-
tttaattggaa-3). The conserved speB gene was amplified with
speB-F (5-ggggatccagattattaagtcttttagcattaggtgga-3) and speB-R
(5-gggtcgacctaaggtttgatgcctacaacagcactttg-3). Platinum PCR
SuperMix (Invitrogen) was used with the following temperature-
cycling parameters: 95 °C for 2 min; 30 cycles of 95 °C for 30 s,
55 °C for 30 s, 72 °C for 1min 30 s; 72 °C for 10min; and 4 °C hold.
WholeGenomeSequenceAnalysis—Genomic fragment libraries
were prepared at the AustralianGenomeResearch Facility with
the Illumina TruSeq DNA library preparation protocol (40).
Random subsets of 1 million read pairs were selected to per-
form readmapping and de novo assembly for comparative anal-
ysis against the publishedM4GAS strainMGAS10750 (RefSeq
accession number NC_008024) (32).
SpeB Assays and Western Blots—SpeB protease activity in
cell-free stationary phase GAS supernatants was determined
using the azocaseinoytic assay (41). Western blot analysis of
stationary phase supernatants was performed as previously
described using rabbit anti-SpeB IgG (Toxin Technology, Sara-
sota, FL) (42).
covRS and ropB Sequencing—covRS PCR products generated
using primers P1 and P12were sequenced byGenewiz (La Jolla,
CA) with primers P1–P12 (22). Sequence analysis of ropB was
performed as described previously using primers RopB-F1–
RopB-R17 (43). Sequences were aligned to the covRS or ropB
sequences from M4 GAS strain MGAS10750 (32) using
MacVector 11.0.4 software.
Expression and Purification of Recombinant HylA Proteins—
The hylA gene, excluding the N-terminal signal peptide and
C-terminal cell wall anchor motif, was PCR amplified fromM4
GAS strain 4063-05 and M1T1 GAS strain 5448 using primers
pQE30-M4-hylAF (5-caccatcaccatcacgatacactgacttcaaattcaaaac-
3), pQE30-M4-hylAR (5-caagctcagctaattccagtacgcggtaagcgtcgt-
tgtc-3), pQE30-M1-hylAF (5-caccatcaccatcacgatacactgacttcaaa-
ttcagaac-3), andpQE30-M1-hylAR (5-caagctcagctaattttattgttga-
ttttgcctgacagga-3). His6 tag expression pQE-30 vector (Qiagen)
was linearized by PCR amplification with primers pQE30-M4-
hylAvF (5-cttaccgcgtactggaattagctgagcttggactcctgtt-3), pQE30-
M4-hylAvR (5-tgaagtcagtgtatcgtgatggtgatggtgatgcgatcct-3),
pQE30-M1-hylAvF (5-caaaatcaacaataaaattagctgagcttggactcct-
gtt-3), and pQE30-M1-hylAvR (5-tgaagtcagtgtatcgtgatggtg-
atggtgatgcgatcct-3). Purified PCR products were assembled
usingGeneArt SeamlessCloning (Invitrogen). RecombinantHis6-
tagged HylA proteins were expressed and purified using TALON
Metal Affinity Resin (Clontech), according to the manufacturer’s
instructions.
Enzymatic Assays—Glycosidase activity assays were per-
formed essentially as previously described (44). HA sodium salt
from rooster comb, chondroitin sulfate sodium salt from shark
cartilage, heparan sulfate sodium salt from bovine kidney, and
chondroitin sulfate B (also known as dermatan sulfate) sodium
salt were purchased from Sigma. The substrates were dissolved
in 50 mM ammonium acetate buffer (pH 6.5), 10 mM calcium
chloride (45). Recombinant HylA (500 or 5,000 pM) and 0.05–
0.30 or 1.0 mg/ml substrates were incubated in the ammonium
acetate buffer at 37 °C. The rate of substrate degradation was
measured by monitoring the increase of A232 over time. The
kinetic parameters of M4 HylA with concentration ranges of
0.05–0.30 mg/ml of HA at 37 °C were calculated using the fol-
lowing formula and Lineweaver-Burk double-reciprocal plots,
1
V0

Km
Vmax

1
S

1
Vmax
(Eq. 1)
V0 is the initial reaction rates (A232/min), Km is the Michaelis-
Menten constant, Vmax is the maximum reaction velocity, and
[S] is the substrate concentration.
Bioinformatic Analysis—The distribution of the HylA-en-
coding gene, hylA, was examined essentially as previously
described (16). Briefly, the SEED and NCBI RefSeq genomic
databases were searched for HylA protein homologs using
BLASTP and subsystem analysis for protein similarity. When
no annotated protein homologs were found in a genome, the
absence of hylA was confirmed by the lack of tBLASTN
matches.
Construction of hylA Mutants—Allelic exchange mutagen-
esis was performed as previously described (16) using primers
hylA-XhoI-upF (5-cggctcgagcacgcgagcacgaacagacttcac-3),
hylA-upR-cat (5-ccagtgatttttttctccattgataaattcctccaatataaaaatga-
gataataaaag-3), hylA-downF-cat (5-tggcagggcggggcgtaaaagcttg-
ctgatcaaggaattgcagctaaaaacaatgctc-3), and hylA-XbaI-downR
(5-cgctctagacgaagcagctactattatggaatctg-3). The precise in-frame
allelic exchange of hylAwith the chloramphenicol resistance gene
(cat) in 5448hylA and 4063-05hylA was verified by PCR and
HylA activity assays (46).
Complementation of hylA mutants—The hylA genes from
GAS strains 4063-05 (serotype M4) and 5448 (serotype M1)
were PCR amplified using forward primerM1-HylA-For-EcoRI
(5-agcgaattcgtgaatacttatttttgcacac-3) or M4-HylA-For-NsiI
(5-agcatgcatctaaatccttaagtctttcttac-3), and reverse primer
HylA-Rev-BamHI (5-agcggatccttattgttgattttgcctgac-3). PCR
products were cloned into the erythromycin-resistant plasmid
pDCerm to create pHylA (expressing activeM4GASHylA) and
pHylA* (expressing inactiveM1GASHylA). The plasmidswere
Hyaluronan and Hyaluronidase in Invasive GAS
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electroporated into 5448hylA to construct complemented
strains 5448hylA pHylA and 5448hylA pHylA*.
Capsule Expression in M4 GAS—The hasABC operon from
M1GAS strain 5448was PCR amplified using primers hasABC-
F-XbaI (5-ggtctagagtgcctatttttaaaaaaactttaat-3) and hasABC-
R-BamHI (5-ggggatccttactttgaatgtgttggtactttac-3) and cloned
into pDCerm. The resultant plasmid, pHasABC,was electropo-
rated into WT 4063-05 and 4063-05hylA to construct
4063-05 pHasABC and 4063-05hylA pHasABC, respectively.
Capsule expression was quantified using the HA test kit as
described above.
Whole Blood Survival—Bacterial survival post 2 h incubation
in whole human blood was analyzed as described previously
(47).
C4BP Pull-down and Adherence Assays—Recombinant His6-
tagged M proteins and the C4BP fragment (C4BP1–2) (48)
were expressed and purified as previously described (37, 38).
C4BP pull-down assays were performed by mixing 10 g of
C4BP1–2 and 20 g of M protein in 50 l of binding buffer
(300mMNaCl, 50 mM sodium phosphate buffer, pH 8.0, 50 mM
imidazole, 0.1% (v/v) Triton X-100) at 37 °C for 30min. 20l of
Ni2	-nitrilotriacetic acid-agarose beads (Qiagen) equilibrated
in binding buffer were added to the protein mixture and incu-
bated for 30 min at 37 °C under agitation. The beads were
washed three times with 200 l of binding buffer and proteins
were eluted by boiling for 5 min in non-reducing 5 SDS-
PAGE sample buffer. Fractions corresponding to unbound and
bound proteins were resolved by non-reducing SDS-PAGE and
visualized with Coomassie stain. Microtiter plate adherence
assayswere conducted according to themethod ofDahesh et al.
(47) with 4g of purified humanC4BP (Complement Technol-
ogy, Tyler, TX).
Fibrinogen Binding—Mid-log phase GAS (A600  0.4) in
10-ml culture volumes was centrifuged, resuspended in 5 ml of
PBS, and 100-l aliquots were added to a round bottom 96-well
plate (Costar). Human Fg conjugated with Alexa Fluor 488
(Molecular Probes) was added to a final concentration of 100
g/ml and the plate incubated at 37 °C for 1 hwith shaking. The
plate was centrifuged at 500  g for 10 min and wells were
washed 3 times with 200 l of PBS. Bacteria were resuspended
in 150 l of PBS and analyzed by flow cytometry. The average
geometric mean of samples without fibrinogen was subtracted
from each strain to adjust for background.
Cell Surface Plasmin Activity—GAS cultures were grown
overnight to stationary phase. The next day, 300 l of culture
was added to 3 ml of THB supplemented with 1 unit/ml of
human plasminogen (Calbiochem) and 7Mhuman fibrinogen
(Calbiochem) to facilitate cell surface plasmin acquisition, or
THB only as the negative control. Cultures were grown to
A600 0.4, divided into 3 1-ml aliquots in siliconized tubes,
centrifuged for 5 min at 6,000  g, and bacterial pellets were
washed oncewith 1ml of sterile PBS. Following resuspension in
200 l of PBS, 10-l aliquots were collected for cfu enumera-
tion, prior to transferring 180 l into V-bottom 96-well plates
(Costar) and adding 20 l of substrate S-2251 (Chromogenix).
The plate was incubated in the dark for 1 h at 37 °C, centrifuged
for 10min at 500 g, and 100l from eachwell was transferred
into a flat bottom 96-well plate (Costar). The A405 was mea-
sured using SpectraMax 250 (Molecular Devices). Cell surface
plasmin activity was calculated as absorbance units/cfu. The
following control wells were used: positive control, 1 unit/ml of
human plasminogen 	 1 g of streptokinase from group C
Streptococcus (Sigma); negative control, 1 unit/ml of human
plasminogen only; substrate negative control, PBS only.
Neutrophil Killing Assays—Humanneutrophils were isolated
from venous blood using the PolymorphPrep system (Axis-
Shield) and resuspended to 2  105 cells/100 l in RPMI
1640	 2% FBS heat inactivated for 30 min at 56 °C. Survival
assays were performed as previously described (47). Briefly,
100 l of neutrophil suspension was seeded into 96-well plates
and 100 l of mid-log phase bacteria in RPMI	 2% heat inac-
tivated FBS were added for a multiplicity of infection of 1 (M4
GAS) or 0.1 (M1 GAS). The assay plate was centrifuged at
500 g for 10min and incubated for 15min at 37 °C	 5%CO2.
Aliquots were serially diluted and plated onto Todd-Hewitt
agar for enumeration. Percent survival was calculated using
bacterial control wells grown under the same conditions with-
out neutrophils.
Systemic Infection Model—Cohorts of 10-week-old female
CD-1 mice (Charles River Laboratories) were inoculated intra-
peritoneally with108 cfu in 200 l of PBS, 5% porcine gastric
mucin (Sigma), and survival was monitored twice daily for 14
days.
Statistical Analysis—Capsular expression levels, SpeB prote-
ase activity, whole blood survival, C4BP binding, fibrinogen
binding, and plasmin activity assayswere compared by one-way
analysis of variance. Neutrophil survival was analyzed using the
Student’s t test. Kaplan-Meier survival curves were compared
using the log-rank test. Differences were considered signifi-
cantly different at p 
 0.05. All statistical analyses were per-
formed with GraphPad Prism version 5.0b (GraphPad Inc.).
Ethics Approval—Permission to collect human blood under
informed consent was approved by the University of California
San Diego (UCSD) Human Research Protection Program. Pro-
cedures used for all animal experiments were approved by the
UCSD Institutional Animal Care and Use Committee.
RESULTS
Typing and Genotypic Analysis Suggest That the M4 GAS
Isolates Are Not Clonal—Over the past few decades, M1 GAS
has been the most frequently isolated serotype from human
infections worldwide (4) and the leading cause of life-threaten-
ing invasive syndromes (5). However, serotype M4 was the
principal serotype associated with a recent report of severe
invasive infections in Queensland, Australia, accounting for
16% of isolates compared with 8% for M1 (34). 17 such M4
isolates from this region, designated SP435–SP451, were
obtained from children aged 1 to 14 years with invasive GAS
infections between 2001 and 2009 (Table 1). SP435 and SP436
were highly virulent strains isolated from brothers hospitalized
for 2–3 weeks (supplemental Table S1). The worldwide resur-
gence of severe invasive GAS infections over the past three
decades has been attributed to the emergence of a single glob-
ally disseminated serotype M1T1 GAS clone (20). To deter-
mine whether the M4 isolates were clonal in origin, genomic
DNA extracts were analyzed by PFGE. Three distinct PFGE
Hyaluronan and Hyaluronidase in Invasive GAS
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patterns were identified, with the majority (65%) of M4 isolates
sharing the same pattern (Fig. 1A). MLST classified the strains
into 2 groups, with 15 of 17 (88%) identified as ST 39 (Table 1).
SP449 and SP451 share a unique and hitherto unidentified
mutS allele (supplemental Table S2), and have yet to be
assigned a ST by the S. pyogenesMLST database.
M4 GAS Are Nonencapsulated and Lack the hasA Gene—A
recent study identified capsule-deficient M4 GAS (33). To
ascertain whether our geographically distinct M4 GAS isolates
were similarly nonencapsulated, mid-logarithmic phase cul-
tures were screened for HA capsule expression levels using a
commercial ELISA-based kit. All M4 isolates were negative for
FIGURE 1. A, PFGE typing of 17 clinical M4 GAS isolates associated with invasive disease. Data are representative of 2 independent experiments. B, mid-log
phase capsule expression levels for M4 strains SP435–SP451 and M1 strain 5448. Values denote arithmetic mean S.E. Data were pooled and normalized to
5448 from 2 independent experiments, each performed in triplicate. C, monosaccharide composition analysis of hydrolyzed glycosaminoglycan (GAG)-
enriched fractions fromWTM4 GAS, encapsulatedWTM1 GAS control strain 5448AP (22), and 1 nmol standards. Abbreviations used are: Fuc, fucose; GalNH2,
galactosamine; GlcNH2, glucosamine; Gal, galactose; Glc, glucose;Man, mannose; GalA, galacturonic acid; GlcA, glucuronic acid.
TABLE 1
Clinical origin of serotype M4 GAS isolates
The table uses the following abbreviations: F, female; M, male; ST, multilocus sequence type; tba, newly identified MLST to be assigned by S. pyogenes MLST database
curators; UTI, urinary tract infection.
GAS isolate Datea DOBb Sex Tissuec emm type emm subtype tee type ST Physician notes
SP435d 20 Feb-01 07 Jul-99 M Blood 4 4.15 4 39 Septic arthritis E. coli UTI
SP436d 20 Feb-01 11 Feb-97 M Blood 4 4.15 4 39 Community acquired sepsis, with knee pain
SP437 24 Jun-02 21 Sep-00 M Blood 4 4.15 4 39 NAe
SP438 06 Jul-06 22 Mar-04 M Blood 4 4.0 4 39 Nonspecific rash, pedal oedema
SP439 21 Aug-06 13 Apr-04 M Blood 4 4.0 4 39 Abscess?
SP440 NA 07 Apr-05 M Blood 4 4.0 4 39 Generally unwell
SP441 11 Apr-07 08 Sep-05 F Blood 4 4.0 4 39 NA
SP442 10 May-07 25 Jan-00 M Blood 4 4.0 4 39 Hand-foot-and-mouth disease?
SP443 01 Nov-07 01 May-02 M Abscess 4 4.0 4 39 NA
SP444 28 Apr-08 19 Feb-06 M Blood 4 4.0 4 39 NA
SP445 13 May-08 01 Dec-93 M Blood 4 4.0 4 39 NA
SP446 29 May-08 12 Jan-06 F Blood 4 4.0 4 39 NA
SP447 05 Sep-08 18 Sep-01 F Tissue 4 4.0 4 39 Severe sepsis with multiorgan failure
SP448 29 Dec-08 27 Feb-04 M Blood 4 4.0 4 39 NA
SP449 02 Feb-09 12 Oct-03 M Blood 4 4.0 4 tba Vomiting	 rashes
SP450 26 May-09 12 Feb-01 M Blood 4 4.0 4 39 Febrile, seizure
SP451 09 Feb-09 12 Oct-03 M Throat 4 4.0 4 tba NA
a Date isolate received; day, month, and year.
b Date of birth; day, month, and year.
cHuman tissue from which M4 GAS was isolated.
d SP435 and SP436 were isolated from brothers; see supplemental Table SI for detailed clinical information.
eNA, data not available.
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capsule expression, compared with M1 GAS positive control
strain 5448 (Fig. 1B). To corroborate the ELISA data, we under-
took monosaccharide composition analysis of hydrolyzed gly-
cosaminoglycan-enriched fractions from WT M4 GAS and
encapsulated M1 GAS control strain 5448AP (22). Glucosa-
mine (GlcNH2) and glucuronic acid (GlcA), the constituents of
HA, were detected for 5448AP (Fig. 1C), verifying capsule
expression in M1 GAS. The double peak near GlcA is charac-
teristic of HA. In contrast, M4GASwas completely deficient in
GlcA and had very small amounts of GlcNH2, compared with
5448AP (Fig. 1C). These data confirm that M4 GAS lack HA
capsule.
Multiplex PCR screening of purified genomic DNA revealed
that none of the M4 isolates contained the essential capsule
synthesis gene hasA (Fig. 2A) (17), consistent with the previous
report (33). In contrast, all M4 isolates were positive for the
control gene, speB, encoding for the ubiquitous cysteine prote-
ase SpeB (Fig. 2A).
M4GAS Lack the hasABC Capsule Biosynthesis Operon—To
validate the absence of hasA and further investigate the
enhanced virulence potential of the newly emerged M4 GAS,
two isolates with different PFGE patterns, SP436 and SP447,
were subjected to whole genome sequence analysis (Fig. 2B).
Comparison of SP436 and SP447 genomic content to the
sequenced M4 genome MGAS10750 (RefSeq accession num-
ber NC_008024) (32) reveals 99% identity at the nucleotide
level with most of the sequence divergence between the strains
confined to mobile genetic elements. Similar to MGAS10750
(33), SP436 and SP447 lack the hasABC capsule biosynthesis
operon, strongly suggesting that this operon is absent in
ancestral M4. The genomic region flanking hasABC is highly
conserved between M4 GAS strains (SP436, SP447, and
MGAS10750) and the M1 reference strain SF370 (RefSeq
accession number NC_002737) (49) (Fig. 2C).
When compared with MGAS10750, the genomes of SP436
and SP447 harbor the same integrative conjugative element
FIGURE 2. A,multiplex PCR screening for hasA, the essential gene for capsule biosynthesis, and control gene speB encoding cysteine protease SpeB. Data are
representative of 2 independent experiments. B, genome-wide comparison of SP436 and SP447 to the published M4 GAS genome MGAS10750 (RefSeq
accession number NC_008024) (32). A total of 7,761,941 and 8,310,842 read pairs were obtained for SP436 and SP447, respectively, corresponding to an
estimated average coverage of 862X and 923X. The draft genomes of SP436 and SP447 consist of 75 and 40 scaffolds, respectively, each concatenated into a
single circular chromosome of an estimated size of 1.89 and 1.78 Mbp with G 	 C contents of 38.25% (SP436) and 38.33% (SP447). The innermost circles
represent the GC content (black) and GC skew (purple/green) of the central reference strainMGAS10750. The BRIG representation shows for each strain, SP436
(blue) and SP447 (green), respectively, from the innermost to outermost, the sequence similarity and distribution of the number of reads mapped onto the
central reference using a window size of 500. The outermost circle represents previously reported regions of difference in MGAS10750, including prophage
elements10750.1 to10750.4 (red) and integrative conjugative elements 10750.RD-1 and 10750.RD-2 (black). M4 GAS lack the hasABC capsule biosynthesis
operon, the location of which is depicted on the outermost ring (orange triangle). C, schematic alignment of the hasABC operon and flanking regions for
serotype M4 (SP436, SP447, MGAS10750) and M1 (SF370). M4 GAS are deficient in hasABC and have conserved flanking regions with M1 GAS (99% sequence
identity).
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10750.RD-1 encoding sortase SrtA, but are missing integrative
conjugative element 10750.RD-2, which confers resistance to
erythromycin (Fig. 2B). SP436 contains the same four
prophages previously identified forMGAS10750, as well as one
additional putative prophage carrying the streptodornase
encoding gene sdn. In contrast, all four prophages in SP447
have undergone substantial deletion events and become rem-
nants, whereas maintaining all their respective cargo genes
intact. Functional annotation of the predicted coding DNA
sequences also revealed that many previously identified viru-
lence factors were present in the SP436 and SP447 genomes,
including streptolysin O, IgG-degrading enzyme IdeS, strepto-
coccal mitogenic exotoxin Z, SpeB, and C5a peptidase, but not
streptococcal inhibitor of complement nor serum opacity
factor.
The Majority of M4 GAS Isolates Are SpeB-negative covRS
Mutants—Mutations within the covRS two-component regula-
tory system have been implicated in the initiation of GAS inva-
sive disease (5, 21). To investigate whether the M4 isolates in
this study underwent selection for covRS mutation in the
human host, we first screened the M4 panel for loss of SpeB
protease activity. A significant proportion ofM4 isolates, 9 of 17
(53%), were negative for SpeB activity (Fig. 3A), suggesting that
some may harbor covRS mutations. Western blot analysis of
stationary phase culture supernatants confirmed that isolates
lacking SpeB activity did not secrete an active 28-kDa SpeB
protease into the extracellular milieu (Fig. 3B). Sequence anal-
ysis of SpeB-negative M4 isolates confirmed that 8 of 9 (89%)
were covRS mutants (Fig. 3C), with 3 isolates (SP436, SP449,
and SP450) harboring the same covS deletion mutation at
nucleotide (nt) 77 resulting in a truncated CovS protein (Table
2). SP438 was the only covR mutant, containing a Cys to Thr
substitution mutation at nt 575 of the covR gene. SP451 con-
tained 2 mutations in ropB, also known as rgg, a transcriptional
regulator associated with the loss of SpeB expression in some
invasive disease isolates (Table 2) (50). Taken together, these
data confirm that several M4 GAS isolates associated with
human invasive disease have either covRS or ropB mutations
eliminating SpeB protease activity (5).
M4 HylA Specifically Degrades HA—Some Gram-positive
bacteria, including Streptococcus pneumoniae (pneumococ-
cus), Streptococcus suis, and Staphylococcus aureus secrete an
active HA-degrading HylA enzyme. Yet, in most clinically rel-
evant GAS serotypes, such as M1, this enzyme is inactivated by
a single nucleotide substitution resulting in an amino acid
change from Asp to Val at position 199 of the lyase (51). The
only reported GAS serotypes with a lyase possessing Asp-199
are M4 and M22 (51). To evaluate the enzymatic activity of
HylA from M4 and M1 GAS, recombinant His6-tagged HylA
protein from each serotype was expressed in Escherichia coli
and purified by TALON affinity chromatography. Recombi-
FIGURE3.A,quantificationof SpeBprotease activity in stationary phase culture supernatants ofM4GAS (SP435-SP451),M1GASpositive control (5448), andM1
GASnegative control (5448AP), a SpeB-deficient covSmutant (22). Eachbardenotes the arithmeticmean S.E. Datawerepooled andnormalized to 5448 from
2 independent experiments, each performed in triplicate. ***, p
 0.001; ns, no significant difference compared with 5448. B, SpeB Western blot analysis of
stationary phase culture supernatants. The 28-kDa SpeB protease band is indicated. C, covRS DNA sequence analysis of M4 GAS isolates. The positions of the
covRSmutations and primers used for sequence analysis (P1–P12) are indicated.
TABLE 2
covRS and ropBDNA sequence analysis of SpeB-negativeM4 GAS iso-
lates from patients with invasive infections
M4 isolate Mutationa Consequenceb
SP436 nt 77 covS Truncation in CovS
SP438 C to T nt 575 covR Thr to Ile aa 192 CovR
SP439 C to T nt 838 covS His to Tyr aa 280 CovS
SP440 C to A nt 1,136 covS Ala to Asp aa 379 CovS
SP441 nt 1,2151,219 covS Truncation in CovS
SP447 G to A nt 780 covS Met to Ile aa 260 CovS
SP449 nt 77 covS Truncation in CovS
SP450 nt 77 covS Truncation in CovS
SP451 C to T nt 347 ropB Ser to Leu aa 116 RopB
SP451 G to T nt 553 ropB Glu to stop codon aa 185 RopB
aMutation positions are based on nucleotide (nt) position in the covR, covS, or
ropB genes, relative to each ATG start codon.
b Substitutions in CovR, CovS, and RopB are based upon amino acid (aa) position
in each open reading frame, relative to each start codon.
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nant M4 HylA was enzymatically active and degraded HA in a
substrate concentration-dependent manner (Fig. 4A). The
kinetic parametersKm andVmax forM4HylAwere 0.440mg/ml
and 0.091, respectively, as estimated from the Lineweaver-Burk
double-reciprocal plot (Fig. 4B). In contrast, recombinant M1
HylA was enzymatically inactive and unable to digest HA (Fig.
4C). M4 HylA was highly specific for HA and did not degrade
other glycosaminoglycans, including heparan sulfate (Fig. 4D),
dermatan sulfate (Fig. 4E), and chondroitin sulfate (Fig. 4F).
The hylA Gene Is Ancestral and hasABC Was Recently
Acquired by Some GAS Serotypes—HylA is well conserved in
closely related genomes including Streptococcus agalactiae, S.
pneumoniae, S. suis, and S. aureus suggesting that hylA is
unlikely to have been independently acquired by these
genomes, butmay rather be ancestral among streptococcal spe-
cies (Fig. 5A; supplemental Table S3). We hypothesize that M1
GAS and other encapsulated serotypes acquired hasABCmore
recently than hylA, resulting in concurrent HA synthesis and
degradation. Preservation of capsule bestows upon GAS resis-
tance to phagocytosis and enhanced survival in vivo, whichmay
have provided selection pressure for inactivating mutations in
hylA. Although current data do not exclude that the hylAmight
be horizontally acquired, the high degree of sequence conser-
vation inHylA proteins among streptococci and other bacterial
species (Fig. 5B; supplemental Table S3) suggests that hylA
acquisition may have been ancestral to the branching of strep-
tococci. It is possible that hylA is notmetabolically essential and
that it might be detrimental to certain bacterial products,
because a few species have lost this gene (e.g. Streptococcus
mutans, Streptococcus uberis, and Streptococcus thermophilus)
(supplemental Table S3).
High Levels of Capsule Can Be Induced in M4 GAS Isolates
Lacking hylA—To assess whether an active HylA would have
the capacity to digest the capsule of the bacterium, we used
precise allelic exchange mutagenesis to delete the hylA gene in
M1GAS strain 5448 (encoding an inactiveHylA). Complemen-
tation ofM1hylAwith a plasmid expressing active HylA from
M4 GAS (pHylA), but not the inactive HylA from M1 GAS
(pHylA*), completely abolished capsule expression (Fig. 6A).
Conversely, to determine whether M4 GAS is capable of syn-
thesizing capsule in the absence of HylA, we constructed a hylA
allelic exchange mutant in M4 GAS strain 4063-05, a human
blood isolate. Transformation of M4 hylA with pHasABC, a
plasmid expressing the hasABC operon fromM1GAS, resulted
in capsule expression (Fig. 6B). However, the amount of capsule
detected for WT M4 GAS transformed with pHasABC (M4
pHasABC) was significantly less, compared with M4 hylA
pHasABC (Fig. 6B). As a corollary, these findings suggest that
HylA inactivation prevents capsule degradation in GAS sero-
types containing the hasABC operon.
Capsule Expression in M4 GAS Does Not Enhance Whole
Blood Survival, Reduces C4BP Binding, and Has No Effect on
Fibrinogen Binding—Encapsulated M4 GAS (M4 pHasABC)
did not display enhanced survival in whole human blood ex vivo
FIGURE 4. A, time-dependent kinetics of recombinant M4 HylA digestion of HA substrate at various concentrations (0.05–0.30 mg/ml). B, Lineweaver-Burk
double reciprocal plot showing 1/V0 versus 1/[S] (R
2  0.9678). V0 represents initial reaction rate, and [S] represents the HA substrate concentration. C,
time-dependent kinetics of recombinant M1 HylA digestion of HA substrate at various concentrations (0.05–0.30 mg/ml). D–F, time-dependent kinetics of
recombinant M4 and M1 HylA (500 or 5,000 pM) digestion of heparan sulfate (1 mg/ml), dermatan sulfate (1 mg/ml), chondroitin sulfate (1 mg/ml), and PBS
negative control. Data are representative of 3 independent experiments, each performed in triplicate.
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comparedwith the nonencapsulatedWTM4 strain (Fig. 6C). In
contrast, whole blood survival forWTM1GASwas superior to
the acapsular M1 hasAmutant (Fig. 6C), consistent with pre-
vious reports (41). Several human pathogens, including S.
aureus (52), S. pneumoniae (53), S. agalactiae (group B Strep-
tococcus) (54), Neisseria gonorrhoeae (55), and certain GAS
serotypes, includingM4 (56), bind human complement regula-
tory protein C4BP to prevent complement deposition and acti-
vation on the bacterial cell surface (57). GAS C4BP binding can
be mediated by certain M proteins, including M4 protein (Fig.
6D and (56)), but notM1 protein (Fig. 6D and Ref. 58). Next, we
assessed whether capsule expression in M4 GAS affects the
binding of purified human C4BP to the bacterial surface. In
comparison to nonencapsulatedWTM4 GAS, ectopic capsule
expression in M4 pHasABC significantly reduced C4BP bind-
ing (Fig. 6E).M4hylA bound less C4BP thanM4WT (Fig. 6E),
suggesting a role for HylA in M4 GAS C4BP binding. Capsule
synthesis in M4 hylA pHasABC exhibited a trend toward
reducedC4BPbinding comparedwithM4hylA; however, this
difference did not reach statistical significance (Fig. 6E).
Human Fg is a plasma glycoprotein involved in the blood
coagulation cascade and wound healing processes (59). Fg
binding by GAS enhances resistance to phagocytosis by pre-
venting complement C3 convertase deposition on the bacterial
surface (60, 61), and forms a proinflammatory supramolecular
network withM protein that activates neutrophils and contrib-
utes to the pathophysiology of streptococcal toxic shock syn-
drome (62). Capsule deficiency in M4 GAS may enhance Fg
binding by fully exposing Fg adhesins on the bacterial surface.
To test this hypothesis, the binding of Alexa Fluor 488-labeled
human Fg to whole bacteria was assessed by flow cytometry.
Nonencapsulated M4 WT, M4 hylA, and M1 hasA bound
equivalent quantities of Fg (Fig. 6F). Capsule biosynthesis inM4
hylA, but neither M4 nor M1WT strains, enhanced Fg bind-
ing (Fig. 6F).
Capsule Enhances M4 GAS Plasmin Activity and Neutrophil
Survival, but Has No Effect on in Vivo Virulence—The accumu-
lation of plasmin activity on the cell surface is correlated with
invasive disease propensity, enabling GAS to degrade host tis-
sue barriers and spread systemically from the site of localized
FIGURE 5. A, maximum likelihood phylogenetic tree of HylA proteins in different streptococcal species. Approximate likelihood ratios are shown for branch
support. B, section of a multiple sequence alignment (using ClustalW) of HylA protein in sequenced GAS strains, with S. pneumoniae used as an outgroup
homolog, showing a Asp to Val substitution that reportedly abolishes the hyaluronidase activity of HylA (51). Only M4 and M22 GAS serotypes are known to
possess an active HylA enzyme (51).
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infection (5).M4GAS is frequently associated with severe inva-
sive human infections (33, 63), so we assessed the capacity of
M4 GAS to acquire plasmin activity. M4 WT and hylA accu-
mulated significantly less plasmin thanWTM1 GAS (Fig. 7A),
the serotype most often associated with severe invasive GAS
infections (4). Capsule expression in WT M4 and M4 hylA
improved plasmin activity (Fig. 7A), and bacterial survival fol-
lowing a 15-min exposure to freshly isolated human neutro-
phils ex vivo (Fig. 7B). However, capsule expression did not
enhance the virulence of WT M4 or M4 hylA in a mouse
model of systemic infection (Fig. 7C). The HylA-deficient
mutant M4 hylA did not display a significant reduction in
virulence compared with M4 WT (Fig. 7C). Together, these
data suggest that capsule expressionmay not provide a survival
advantage for M4 GAS.
DISCUSSION
Aftermore than a century of research, it is generally accepted
that the HA capsule is a major virulence factor, endowing GAS
with a protective physical barrier, molecular mimicry, resis-
tance to opsonophagocytosis, and the ability to interact with
epithelial cells (6, 7). HA capsule is required for colonization of
the upper respiratory tract and production of invasive infec-
tions in animalmodels (10–13), and contributes to humanpha-
ryngeal and invasive infections (13, 14, 19). In this investigation,
we report that nonencapsulated serotype M4 GAS was a fre-
quent etiologic agent of severe invasive diseases in children.
Molecular genetic interrogation of a panel of 17 invasive disease
isolates identified 3 distinct PFGE patterns and 2 MLSTs. The
majority of isolates were SpeB-negative covRS mutants, a dis-
tinguishing feature of hypervirulent GAS. All M4 isolates
lacked the hasABC capsule biosynthesis operon and did not
produce detectable HA capsule. Induction of capsule expres-
sion in M4 GAS abrogated C4BP binding, an important
immune evasion mechanism to subvert complement attack
(64), and failed to enhance survival in human blood and viru-
lence in a mouse model of systemic infection. These data dem-
onstrate that the HA capsule is not essential for GAS to cause
life-threatening invasive infections in humans.
M4 and M22 GAS serotypes secrete active HylA, an enzyme
that degrades the HA present in the GAS capsule andmamma-
lian connective tissues. Other serotypes contain a single nucle-
otide mutation in hylA resulting in Asp to Val substitution at
amino acid position 199 in the putative substrate-binding site
that completely abolishes HylA enzymatic activity (51). In this
study, we demonstrate that capsule production is abolished in
M1 strain 5448 expressing the hylA gene fromM4GAS. Signif-
icantly, transformation of M4 hylAwith a plasmid expressing
the hasABC operon fromM1GAS induced capsule expression.
These findings demonstrate that M4 GAS has the capacity to
synthesize capsule, and that its capsule is stable in the absence
of a functional HylA enzyme. However, capsule expression in
M4 GAS reduced C4BP binding and neither enhanced whole
FIGURE 6.A, capsule expression levels ofWT clinicalM1GAS isolate 5448 and isogenichylAmutant. TheM1hylAmutantwas complementedwith a plasmid
expressing the inactive hyaluronidase (HylA) fromM1GAS (pHylA*), or the activeHylA fromM4GAS (pHylA).B, capsule expressionofWT clinicalM4GAS isolate
4063-05 and isogenichylAmutant. M4WT andhylAwere transformedwith a plasmid expressing the hasABC capsule synthesis operon (pHasABC) or empty
vector (pDCerm). C, whole blood survival of nonencapsulated WT M4, encapsulated M4 (M4 pHasABC), nonencapsulated hylA mutant (M4 hylA), encapsu-
lated hylAmutant (M4hylA pHasABC), encapsulatedM1GAS, andM1GAS acapsular control (M1hasA) following a 2-h incubation inwhole human blood ex
vivo.D, association of His6-taggedC4BP1–2withM4protein in co-precipitation (pull-down) assays. C4BP1–2wasmixedwithMprotein in binding buffer for
30min at 37 °C. Ni2	-nitrilotriacetic acid-agarose beadswere added and incubated for 30min at 37 °C. The beadswerewashedwith binding buffer to remove
unboundprotein. Boundproteinwas eluted by boiling in non-reducing sample buffer. Fractions corresponding to unbound andboundproteinwere resolved
by non-reducing SDS-PAGE and visualized with Coomassie stain. E, C4BP binding of nonencapsulated M4 GAS (WT and hylA), encapsulated M4 GAS (M4
pHasABC and hylA pHasABC), and encapsulated WT M1 GAS. F, fibrinogen binding of nonencapsulated M4 GAS (WT and hylA), encapsulated M4 GAS (M4
pHasABC andM4hylA pHasABC), encapsulatedWTM1 GAS, and nonencapsulatedM1 GAS (M1hasA). All values denote arithmetic mean S.E. Data were
pooled and normalized from 2 independent experiments, each performed in triplicate. *, p 
 0.05; **, p 
 0.01; ***, p 
 0.001; ****, p 
 0.0001; ns, not
significantly different.
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blood survival nor virulence in vivo, suggesting that encapsula-
tion may not provide a survival advantage for this serotype.
Mouse and other vertebrate models of GAS infection have sig-
nificant limitations and drawbacks because GAS is a human-
adapted pathogen. Therefore, we cannot exclude the possibility
that encapsulated M4 GAS would be more virulent in the
human host. The absence of capsule in HylA-expressing sero-
type M4 and M22 GAS strains (33, 51) suggests a competitive
co-evolution between HylA and capsule; however, hyaluroni-
dase expression by encapsulated GAS was reported more than
50 years ago (65–67). Furthermore, some strains of the closely
related group C Streptococcus, a bacterial pathogen capable of
causing human disease (although less frequently than GAS),
naturally co-express capsule and a functional hyaluronidase
(65, 67).
Highly virulent nonencapsulated strains have been reported
for several human bacterial pathogens, including S. agalactiae
(68), Haemophilus influenzae (69), and Neisseria meningitidis
(70). In the majority of GAS serotypes containing intact covRS
loci, encapsulation provides significant advantages over non-
encapsulation such as molecular mimicry, resistance to phago-
cytosis, and enhanced adherence to host epithelial cells. The
reason for the unsuccessful acquisition of hasABC or loss
thereof remains unclear; however, M4 GAS may possess addi-
tional antiphagocytic factors and adhesins to thwart the host
immune response and promote the disease process. Under-
standing the underlying molecular pathogenesis of nonencap-
sulated GAS invasive disease may augment the development of
a new generation therapeutics and provide better health out-
comes in the fight against this globally important human
pathogen.
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